We are led by an exceptional team of drug development and microbiome experts with vast experience in the discovery, development, regulatory approval, and successful commercialization of a wide range of therapeutic products.
President, Chief Executive Officer
Eric Shaff is the President and Chief Executive Officer of Seres. Mr. Shaff was previously the Executive Vice President, Chief Operating and Financial Officer of Seres. He has more than 15 years of experience working in leadership roles in biotechnology finance, corporate development, and capital markets. Prior to joining Seres, he was Vice President, Corporate Finance, at Momenta Pharmaceuticals, where he helped manage Momenta’s accounting, finance, planning, and procurement functions, as well as contributing to Momenta’s investor relations efforts. Prior to joining Momenta, Mr. Shaff was Vice President, Finance, of Genzyme’s Rare Genetic Disease Division, responsible for a global portfolio of products. Mr. Shaff held several positions at Genzyme in business unit finance, corporate finance, and corporate development. Prior to Genzyme, Mr. Shaff worked in corporate finance at Pfizer and worked in investment banking for Broadview International (now Jefferies LLC). Mr. Shaff earned his B.A. from the University of Pennsylvania in political science and economics and his M.B.A. with a concentration in finance from the Johnson Graduate School of Management at Cornell University.
John Aunins Ph.D.
Executive Vice President, Bioprocess & Manufacturing and Chief Technology Officer
John Aunins is the Executive Vice President of Bioprocess & Manufacturing and the Chief Technology Officer of Seres. He has more than 26 years of experience in the biotechnology industry, with a focus in bioprocess development, manufacturing support, and project leadership. Prior to joining Seres, he led process and product development teams at Merck Research Laboratories for Vaqta®, Varivax®, Zostavax®, ProQuad®, Rotateq®, and Gardasil®. The Vaqta and Gardasil process teams were awarded with ACS Industrial Biotechnology Awards for innovation, contribution to bioengineering, and societal impact. He is a Fellow of the American Institute for Medical and Biological Engineering, and an adjunct Full Professor at the Instituto de Tecnologia Química e Biológica (ITQB) in Oeiras, Portugal. He has authored over 50 articles and book chapters, and has chaired five international conferences in vaccines and bioprocess technology. Dr. Aunins earned his Ph.D. in chemical engineering from MIT in 1989 under Institute Professor Daniel I.C. Wang.
Kelly M. Brady
Vice President, Clinical Operations
Kelly Brady is the Vice President of Clinical Operations at Seres. Throughout her 13-year career she has held positions of increasing responsibility in clinical operations and clinical program management. Prior to joining Seres, Kelly was Senior Director and Global Clinical Program Lead at Akebia, where she oversaw pivotal programs in anemia due to chronic kidney disease. She also previously held roles in Operations and Program management at Acetylon, where she worked on the company’s acquisition by Celgene. Prior to Acetylon, she was the Global Phase 3 Clinical Operations Leader at Millennium Pharmaceuticals at Takeda, overseeing the Adcetris trials in Hodgkins Lymphoma across 29 countries. She also worked as a member of the operations team at Osiris Therapeutics, managing global GVHD studies and working on the stem cell therapy, Prochymal. Kelly holds a Bachelor’s degree in Neuroscience from Lafayette College and a Master’s degree in Biotechnology from Johns Hopkins University.
Vice President, Principal Financial Officer
Marcus Chapman is Vice President, Principal Financial Officer at Seres. Mr. Chapman has almost two decades of experience within the biopharmaceutical industry. Before joining Seres, he served as Senior Director of Finance and Interim Head of Finance at Takeda Oncology. In these roles, Mr. Chapman oversaw finance functions supporting U.S. sales, U.S. and global marketing, operations, global medical affairs and manufacturing. Prior to Takeda, he held senior roles at Clarion Healthcare Consulting and Strategic Decisions Group. He began his career at LaSalle Partners in their Investment Banking and Investment Management groups. Mr. Chapman received his Bachelor of Arts in economics from Wheaton College and his MBA from The Tuck School at Dartmouth.
Gloria G. Cosgrove
Vice President, Quality Systems
Gloria Cosgrove is Vice President, Quality Systems (Quality Assurance and Quality Control) at Seres. She has over 30 years of experience in the biopharmaceutical industry and as a leader in quality systems. Prior to joining Seres, she held leadership positions within quality at Synageva BioPharma, Regeneron and Boehringer Ingelheim, specializing in process development, GxP quality management and preparation and conduct of regulatory inspections from global regulatory agencies, including the FDA, EU, MHRA, Health Canada and PMDA in Japan. In addition to her current role at Seres, Gloria also serves as President of a small non-profit Board in Connecticut. She received her Bachelor’s degree in Special Education and Psychology from Utah State University.
Thomas J. DesRosier, Esq.
Executive Vice President, Chief Legal Officer and Secretary
Thomas J. DesRosier is the Executive Vice President, Chief Legal Officer and Secretary of Seres. He brings more than 30 years of experience in the biopharmaceutical industry. Prior to joining Seres, he served as Chief Legal and Administrative Officer at ARIAD Pharmaceuticals, and prior to that held the same position at Cubist Pharmaceuticals where he led the negotiation of the acquisition of Cubist by Merck. Previous to that, he served as Senior Vice President and General Counsel, North America of Sanofi, a position he assumed in 2011 after Sanofi acquired Genzyme Corporation, where he was Senior Vice President and Chief Legal Officer. Prior to his 12-year tenure at Genzyme, Mr. DesRosier held senior legal positions at Wyeth Pharmaceuticals, predecessor Genetic Institute, and E.I. DuPont de Nemours. He received his J.D. from Wake Forest University School of Law and his Bachelor of Arts in chemistry from the University of Vermont.
Matthew Henn, Ph.D.
Executive Vice President, Chief Scientific Officer
Matthew Henn is the Executive Vice President and Chief Scientific Officer of Seres. He has more than 16 years of combined research experience in microbial ecology, genomics, and bioinformatics that spans both environmental and infectious disease applications. Dr. Henn's research has focused on the development, implementation, and application of genomic technologies in the area of microbial populations and their metabolic functions. Prior to joining Seres, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard.
He has authored over 60 peer-reviewed publications in microbiology and bioinformatics, and has led multiple large-scale international genomic projects. He has served as a consultant for the WHO’s Grand Challenges in Genomics for Public Health in Developing Countries, as a scientific advisor for the National Institutes of Health’s Viral Pathogen Bioinformatics Resource Center, and as an ad-hoc reviewer and editor of many peer-reviewed journals. Dr. Henn earned his Ph.D. in ecosystem sciences from the University of California at Berkeley, where he was a NASA Earth Systems Sciences Fellow, and trained as a NSF Postdoctoral Fellow in microbiology at Duke University.
Kevin Horgan, M.D.
Executive Vice President, Chief Medical Officer
Dr. Horgan has contributed to the development and approval of multiple therapeutics across immunological and oncology indications. Most recently, Dr. Horgan was Vice President of Clinical Development at AstraZeneca, where he led the development of combination immune-oncology programs. Dr. Horgan earlier co-founded Tucana Health, a microbiome diagnostics company. Previously, Dr. Horgan held Chief Medical Officer roles at Soligenix and Coronado. Prior to those roles, he was Vice President of Clinical Immunology at Centocor during the development and approval of Remicade, Stelara and Simponi, approved for inflammatory bowel disease indications. Dr. Horgan began his industry career at Merck, following positions in academic medicine at the University of California, Los Angeles and immunologic training at the National Cancer Institute. Dr. Horgan earned his medical degree from University College Cork in Ireland. He did his medical residency on the Osler Service, at the Johns Hopkins Hospital.
Barbara McGovern, M.D.
Vice President, Medical Affairs
Barbara McGovern is VP of Medical Affairs at Seres. Dr. McGovern has over 25 years of experience in infectious diseases. Prior to joining Seres, she served as Medical Director in the Medical Affairs Division at AbbVie and helped to launch Viekera Pak for treatment of hepatitis C virus (HCV) infection. At AbbVie, Dr. McGovern was recipient of the “2015 President’s Award” in recognition of successful execution of 7 major publications in the New England Journal of Medicine, Lancet and JAMA. She also authored more than 50 journal articles, editorials, and textbook chapters on HIV and HCV and was an Associate Editor of Clinical Infectious Diseases. Dr. McGovern has also served as a member of the Antiviral Advisory Committee for FDA and as a panel guideline member for the Department of Health and Human Services. She earned her undergraduate degree from Queens College, CUNY, her M.D. at Albert Einstein College of Medicine and completed her internship, residency and infectious disease fellowship at Tufts Medical Center.
Carlo Tanzi, Ph.D.
Carlo Tanzi joined Seres in November 2015 as Head of Investor Relations and Corporate Communications. He has over 12 years of biotechnology industry experience in finance, program management, and investor relations. Prior to joining Seres, Carlo spent 9 years at Biogen in positions of increasing responsibility, most recently as an Investor Relations Officer. Carlo previously held roles in Biogen’s Finance and Corporate Development groups, including as the Program Management Lead for Tysabri® and Tecfidera® during Phase 3 development, life cycle management activities, and commercialization. Earlier in his career, Carlo was a healthcare management consultant at Health Advances. He earned a B.A. in biology from the University of Rochester and a Ph.D. in cell and molecular biology from the University of Pennsylvania. Carlo has been a member of the National Investor Relations Institute since 2013.
Sherry Weigand, Ph.D.
Vice President, Clinical Science
Sherry Weigand is the Vice President of Clinical Science at Seres. She is a pharmaceutical industry executive with 20+ years of experience and accomplishments – Seres Therapeutics, Shire, Baxalta, Takeda, Novo Nordisk and Procter and Gamble Pharmaceutical. Prior to Seres, Sherry was a Global Program Lead and Global Clinical Development Lead at Shire, Baxalta, and Takeda, overseeing clinical development programs across multiple therapeutic areas, including neurological disorders, immunological and inflammatory diseases, metabolic disease, vaccine, gene therapy for hemophilia disease and microbiome therapy. In these roles, she successfully led global teams through all phases of clinical development, global regulatory submissions and label negotiation for product registrations in the U.S., EU, Japan, and China. Sherry also previously served as a medical doctor at Beijing Chao-Yang Hospital in China. Sherry received a Bachelor of Medicine from Beijing Medical College and a Ph.D. in Microbiology and Immunology from Louisiana State University. She completed a postdoctoral fellowship at the University of Pittsburg Medical School, focusing on humoral immune response to HIV infection.
Jennifer R. Wortman
Vice President, Bioinformatics
Jennifer Russo Wortman is the Vice President of Clinical Discovery and Research Technology at Seres, overseeing multi-omic microbiome data generation, algorithm development and integrative data analysis, as well as the computational infrastructure supporting our reverse translation platform. Prior to joining Seres, Jennifer was the Director of Microbial Informatics at the Broad Institute, responsible for the software development and analytical strategies supporting the NIAID-funded Genome Center for Infectious Diseases (GCID). That followed three years as Associate Director of Bioinformatics at the Institute for Genome Sciences (IGS) at the University of Maryland School of Medicine, where she was the co-Principal Investigator of the Human Microbiome Project's Data Analysis and Coordination Center (HMP DACC). She has over 70 peer-reviewed publications and made significant contributions to the published genome analyses of humans, mice, mosquitos and the fruit fly as well as diverse pathogenic fungi, parasites, and bacteria.
Vice President, Human Resources
Jeff joined Seres in 2014 bringing 18 years of experience helping organizations and individuals adapt to periods of growth, mergers, and significant changes. Most recently, Jeff served in various HR leadership roles at Millennium Pharmaceuticals (later Takeda) since 2002. Navigating through massive restructuring, product divestiture, a CEO/leadership transition, and then ultimately launching a drug, Jeff helped build a culture that allowed Millennium to become a perennial leader among Fortune magazine’s 100 Best Companies To Work For. Prior to Millennium, Jeff was a Senior Business Partner for PTC, driving HR strategy in support of a global engineering software business with offices in over 30 countries. Jeff earned his B.S. degree from Indiana University and his M.S. degree in Industrial/Organizational Psychology from Springfield College.